BioCentury
ARTICLE | Clinical News

FX006: Phase III started

February 9, 2015 8:00 AM UTC

Flexion began a double-blind, international Phase III trial to compare a single dose of 40 mg intra-articular FX006 vs. both placebo and 40 mg intra-articular immediate-release TCA in about 450 patien...